Global Cardiac POC Testing Market – Overview, Trends, and Forecast
According to recent insights from Custom Market Insights (CMI), the Global Cardiac Point-of-Care (POC) Testing Market was valued at approximately USD 1.2 billion in 2021. It is projected to reach around USD 2.89 billion by 2030, growing at a Compound Annual Growth Rate (CAGR) of 6.5% during the forecast period from 2022 to 2030. This consistent growth is driven by increasing demand for rapid diagnostic solutions, particularly in cardiovascular care.
What is Cardiac POC Testing?
Cardiac Point-of-Care (POC) Testing refers to diagnostic procedures conducted at or near the site of patient care, rather than in a centralized laboratory. These tests are primarily focused on detecting cardiovascular-related conditions, enabling quicker diagnosis and treatment decisions.
POC testing typically involves a blood test used to assess parameters such as cholesterol levels and blood coagulation. These insights help healthcare professionals evaluate a patient’s risk of thrombosis, coagulation issues, or cardiac arrest.
Moreover, cardiac POC testing includes troponin and brain natriuretic peptide (BNP) tests, which are critical in identifying serious heart conditions like:
Myocardial infarction (heart attack)
Coronary artery disease
Heart failure
One of the main advantages of cardiac POC testing is its speed—in many cases, results are available within an hour of collecting the test sample, significantly improving treatment timelines and outcomes.
? Explore the full report here: Cardiac POC Testing Market – CMI
Market Dynamics
Drivers
One of the major driving forces of this market is the rising global prevalence of heart-related disorders. As heart disease continues to be a leading cause of death, the need for early, accessible, and accurate diagnosis is growing.
For example, data from the National Medicine Library (July 2020) indicated that Ischemic Heart Disease (IHD) affects roughly 126 million people worldwide, equating to approximately 1.72% of the global population. The increasing incidence of such conditions will significantly drive the demand for cardiac POC testing technologies.
Restraints
Despite the promising growth, several factors are restraining market expansion:
Shortage of trained healthcare professionals skilled in operating cardiac POC devices
High costs associated with cardiac POC testing equipment
Expensive manufacturing processes and the need for advanced machinery
These challenges are pushing some healthcare providers and manufacturers to consider alternative diagnostic technologies, which could potentially slow the adoption of cardiac POC testing.
Opportunities
On the positive side, the adoption of high-sensitivity and premium-priced POC troponin tests is presenting significant growth opportunities. As healthcare systems worldwide continue shifting toward value-based care models, point-of-care diagnostics are increasingly seen as a way to improve efficiency and reduce costs.
Additionally:
Rapid results and ease of use are attracting more physicians to adopt cardiac POC devices.
Growing public awareness about cardiovascular health and a wider push for preventive healthcare are enhancing consumer willingness to invest in early diagnostics.
As more consumers embrace healthier lifestyles, their medical purchasing power is also increasing, creating a favorable market environment for these technologies.
Challenges
However, several operational and logistical challenges remain:
Improper handling and poor maintenance of POC analyzers
Use by untrained staff can lead to inaccurate results
Lack of regular calibration and quality controls
Limited cost-efficiency due to a high number of analyzers and expensive reagents
Inadequate documentation and inconsistent diagnostic protocols
These factors collectively pose a challenge to the consistent performance and acceptance of cardiac POC testing, especially in low-resource settings.
? Download a free sample of the report: Request Sample Copy
Market Segmentation Insights
By Product Type
The market is segmented by product type into:
Cardiac Markers Tests
Analyzers
Others
Among these, the cardiac markers test segment led the market in 2021 and is expected to continue dominating throughout the forecast period. These tests involve analyzing proteins, enzymes, and hormones in the blood to detect cardiovascular events.
Cardiac biomarker testing is essential for identifying acute coronary syndromes (ACS) and cardiac ischemia, and for assessing the severity of heart dysfunction. Their role in early detection significantly boosts their adoption, contributing to the strong market performance of this segment.
By End-User
Based on end-users, the market is categorized into:
Research Laboratories
Hospitals
Ambulatory Surgical Centers
Diagnostic Laboratories
Others
In 2022, the hospital segment held the largest market share, and it is anticipated to maintain its dominance through 2030.
Hospitals, especially tertiary care and multispecialty facilities, rely heavily on cardiac POC testing due to:
High performance and accuracy
Ease of use
Faster turnaround times
These characteristics have made POC testing a standard component of modern cardiac care within hospitals.
Regional Analysis
Geographically, the market is analyzed across:
North America
Europe
Asia-Pacific
LAMEA (Latin America, Middle East, and Africa)
Among these, Asia-Pacific emerges as the leading region in terms of cardiac POC testing utilization. Factors contributing to this dominance include:
Rapidly growing population base
High susceptibility to chronic heart diseases
Increasing adoption of cost-effective diagnostic tools in rural and underserved areas
The widespread use of POC tests in hospitals, diagnostic centers, and laboratories across Asia-Pacific is expected to propel continued regional growth.
Key Market Players
The report provides a detailed competitive analysis, highlighting major companies operating in the global cardiac POC testing market:
LifeSign LLC
Medtronic plc
Nano-Ditech Corporation
Nexus Dx Inc.
PTS Diagnostics
Bio-Rad Laboratories Inc.
F. Hoffmann-La Roche AG
Nova Biomedical Corporation
Trividia Health Inc.
Sekisui Diagnostics
Nipro Corp.
Trinity Biotech
Orasure Technologies, Inc.
Spectral Medical Inc.
These companies are actively involved in product innovation, strategic partnerships, acquisitions, and geographic expansion, contributing significantly to the competitive landscape of the market.
https://www.custommarketinsights.com/report/cardiac-poc-testing-market/
